No Data
Intensifying competition in the domestic CRO market is eroding profits, BiDe Pharmaceutical claims it will strengthen its overseas market | Direct hit earnings conference
①Due to factors such as the slowdown in investment and financing for innovative drugs, increased competition among CRO companies, BeiDe Medicine's domestic revenue continues to decline, dragging down overall performance and leading to a sharp decrease in net income; ②In contrast, overseas market revenue remains growth, BeiDe Medicine's director, Dai Lan, revealed that there will be corresponding increase in overseas market BD personnel to carry out promotional work in the future.
Hunan oil pump: plans to invest in the construction of two large overseas bases, with an annual output of 3.5 million units of new energy electronic pump project in progress | Earnings conference
① Currently, Hunan Oil Pump's two major overseas production bases are preparing for construction according to plan; ② To observe the future production capacity increase, one should look at the progress of the annual production of 3.5 million new energy electronic pump intelligent manufacturing project.
Fushan Precision: Acquisition matters are currently being discussed with multiple parties | Directly targeting the earnings conference.
①Zheng Guangwen, the chairman of Fuchuang Precision, stated today that the company's current orders are quite sufficient, the operation is stable, and the existing production capacity can effectively meet customers' order delivery needs; ②Regarding the acquisition of 100% equity of Yisheng Precision, Zheng Guangwen stated that the acquisition is currently under discussion with multiple parties. Once completed, the acquisition will help enhance the company's comprehensive service capabilities.
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
The merger drama of Shijiazhuang Kelin Electric is over, and shareholders from all parties jointly formed the "cabinet" with many former executives retaining their positions. Grassroots employees: "We have confidence now."
The merger drama of Shijiazhuang Kelin Electric has come to an end, and the shareholders of all parties have finally reached a consensus and successfully completed the joint "cabinet formation", with key management positions being filled by the original management of the company. HaiXinWangnengfang obtained the positions of Chairman and Vice Chairman, and the nominee from Shijiazhuang Guotou obtained the positions of General Manager and Chairman of the Supervisory Board. All parties expressed their intention to jointly promote the company's development.
The longest shareholder meeting in history lasted for two days without ending. Hisense Network may take control of the majority of seats on the board of directors of Shijiazhuang Kelin Electric.
Shijiazhuang Kelin Electric's shareholder meeting continues to set a record for the longest duration of A-share listed company shareholder meetings. The majority of the seats on the board of directors of Hisense Networks may have been determined.